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Thalidomide is effective in the treatment of multiple myeloma. The immunomodulatory drug and thalidomide analogue lenalidomide
is currently in late stage clinical development for MDS and multiple myeloma. This minireview highlights the course of initial and
ongoing lenalidomide clinical development in oncology with reference to earlier thalidomide studies.
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PRECLINICAL DEVELOPMENT OF IMiDs
s
The IMiDs
s are immunomodulatory thalidomide analogues
designed to optimise certain properties including anticancer
properties, but they lack or minimise much of the toxicity
associated with thalidomide (Bartlett et al, 2004a). Extensive
preclinical testing of this class of compound, involving pharma-
cology, pharmacokinetics and toxicity, has led to the identification
of lenalidomide (CC-5013; REVLIMID
s) for clinical development
in the oncology setting.
While the IMiDs share many of thalidomide’s biological
properties, the relative potency and range of these effects vary
quite dramatically from each other and from thalidomide. Thus,
each molecule cannot be assumed to have the same overall
biological effects or therapeutic properties as thalidomide or other
IMiDs. Preclinical data continue to support the clinical application
of lenalidomide in cancer. For example, in contrast to thalido-
mide’s teratogenicity, lenalidomide is nonteratogenic in the New
Zealand rabbit preclinical model, which is the most sensitive
animal model for thalidomide-associated teratogenicity.
The IMiDs have many different effects on biological systems and
the combination of these properties probably accounts for their
antineoplastic activity. IMiDs are antiangiogenic (Dredge et al,
2002a; Lentzsch et al, 2002) and T-cell costimulatory (Haslett et al,
1998). IMiDs also activate the innate component of the immune
system: enhanced natural killer cell cytotoxicity leading directly to
multiple myeloma cell lysis (Davies et al, 2001). The ability of
IMiDs to activate innate immune responses may be crucial to the
generation of effective adaptive antitumour responses in vivo,
although this area remains relatively unexplored, as has a potential
role for IMiDs in the enhancement of protective antitumour
immunity (Dredge et al, 2002b).
Certain IMiDs appear to possess direct in vitro antimyeloma
activity (Hideshima et al, 2000); primary human multiple myeloma
(MM) cells derived from the bone marrow of patients resistant to
chemotherapy are susceptible to IMiD-induced growth arrest.
IMiDs may also potentiate the effects of TNF-related apoptosis-
inducing ligand (TRAIL), dexamethasone and proteasome inhibi-
tors that are currently used as antimyeloma therapies. These IMiDs
can also interfere with myeloma cell–bone marrow stromal cell
interactions by affecting adhesion molecule expression, which
might be crucial for MM cell growth and survival, and prevent the
upregulation of IL-6 and vascular endothelial growth factor
(VEGF), which is involved in angiogenesis (Gupta et al, 2001).
CLINICAL DEVELOPMENT OF LENALIDOMIDE
Thalidomide is currently indicated in the US only for the
cutaneous manifestations of erythema nodosum leprosum (ENL),
a reactional state of leprosy. A regulatory application is under
review by the US Food and Drug Administration for use in MM. In
Australia, New Zealand, Turkey and Israel, thalidomide is
approved for the treatment of MM after the failure of standard
therapies, as well as for ENL. Teratogenicity is the most serious
potential side effect; therefore, thalidomide is available only under
a restricted distribution system. In order to understand how IMiDs
with their broad preclinical activities might affect human disease,
Celgene embarked on a strategy to evaluate thalidomide’s
therapeutic activity in small groups of patients with a wide variety
of diseases. Larger trials in more targeted disease states followed,
based on the early signals obtained during these small clinical
trials. Discussed below will be a brief review of what has been
observed with thalidomide and lessons learned for further
development of lenalidomide, the lead IMiD chosen for use in
the oncology setting.
Multiple myeloma
Multiple myeloma is an incurable B-cell malignancy characterised
by the clonal proliferation of malignant cells, usually in the bone
marrow, that leads to the production of a monoclonal immuno-
globulin. Multiple myeloma afflicts 14000–15000 new patients
annually in the US. The current median survival rate for
symptomatic patients is 3–5 years. High-dose chemotherapy
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www.bjcancer.com(Melphalan) combined with transplantation of haematopoietic
stem cells increases the rate of complete remission and extends
event-free and overall survival. However, relapse rates are very
high and few salvage therapies are available. Antiangiogenic
therapy is a viable option for the treatment of patients with MM
since it is associated with prominent bone marrow vascularity, the
degree of which correlates with prognosis. In addition, plasma
levels of various proangiogenic molecules are elevated in active
MM. It is also evident that circulating endothelial progenitor cells
(EPC) contribute to angiogenesis in MM and that the elevation of
EPC levels correlates with disease activity. Interestingly, inhibition
of EPC is associated with patient response to thalidomide (Zhang
et al, 2005). Also, since adhesion to bone marrow stroma is
associated with chemotherapy resistance, thalidomide and lenali-
domide therapy might theoretically make previously chemo-
therapy-resistant tumours sensitive by affecting stromal–myeloma
cell interactions. The clinical strategy for the use of thalidomide in
MM was to determine its activity as monotherapy, followed by
trials using it with other drug combinations including drugs that
were not previously effective in treating patients.
Monotherapy thalidomide trials in advanced relapsed/refractory
(Kumar et al, 2003; Richardson et al, 2004) as well as previously
untreated asymptomatic MM (Rajkumar et al, 2003; Weber et al,
2003) (also known as ‘smouldering’ or indolent myeloma) have
consistently shown partial response rates (SWOG criteria) of
approximately 30%, with an acceptable safety profile. Thalidomide
combined with dexamethasone in relapsed, refractory MM induces
a partial response in 56% of patients (Palumbo et al, 2004a). In
newly diagnosed patients, thalidomide and dexamethasone therapy
resulted in 64% partial responses (Rajkumar et al, 2002). A
planned interim analysis of a phase III Eastern Cooperative
Oncology Group study in newly diagnosed MM patients demon-
strated a significantly higher response rate in patients randomised
to thalidomide with dexamethasone than in those on dexametha-
sone alone (80 vs 53%, respectively, P¼0.0023, n¼109). Grade 3–
4 toxicities were higher in the combination therapy arm,
particularly deep vein thrombosis (Rajkumar et al, 2004a). The
results of this ECOG trial have been submitted to the FDA to
support the supplemental New Drug Application (sNDA) for the
use of thalidomide in the treatment of MM.
Although uncommon with single agent thalidomide, there may be
potential for thromboembolic events when thalidomide is combined
with dexamethasone and other agents, which has led to preliminary
evaluation of various regimens as prophylaxis in high-risk patients.
Full therapeutic dose anticoagulation (either coumadin or low
molecular weight heparin) has been used in patients who are at
higher risk for DVT, with some evidence of prophylactic effect
(Zangari et al, 2001) and aspirin may have a role in reducing
incidence associated with thalidomide and DVd (Baz et al, 2004).
While being anticoagulated as a treatment for a DVT, patients can be
continued on thalidomide treatment (Zangari et al, 2001).
Encouraging results have also been observed with thalidomide
when combined with a corticosteroid and a chemotherapeutic
agent. A variety of such combinations of oral medications in newly
diagnosed patients have produced greater than 80% partial
responses and up to 26% complete responses (Dimopoulos et al,
2004; Palumbo et al, 2004b). Increased toxicities, including venous
thromboses, have been seen with the melphalan/prednisone/
dexamethasone (MPT) regimen (neither the pulsed melphalan/
dexamethasone/thalidomide (MDT) nor the cyclophosphamide/
thalidomide/dexamethasone (CTD) regimen reported increased
DVT incidence), suggesting that the sequential administration of
chemotherapy and thalidomide may result in higher responses,
without an increase in DVTs (Dimopoulos et al, 2004). Thalido-
mide’s addition to other commonly used combination therapies,
such as VAD or Doxil/Vincristine/dexamethasone (DVd), results
in almost a doubling of the response and complete response rate.
Increased venous thromboses and infections may be controlled or
prevented with low molecular heparin or low-dose aspirin and
antibiotics, respectively.
Thalidomide has been observed to have activity in other
haematological diseases and cancers, including myelodysplastic
syndromes, MDS (Raza et al, 2001), chronic lymphocytic
leukaemia (Furman et al, 2005), myelofibrosis (Mesa et al, 2004),
Waldenstrom’s macroglobulinaemia (Dimopoulos et al, 2003),
prostate cancer (Dahut et al, 2004) and brain cancer (Fine et al,
2003).
On the basis of the thalidomide experience, lenalidomide was
evaluated as an oral MM treatment in two Phase III clinical studies
in patients with relapsed, refractory MM. Thalidomide-like side
effects, such as somnolence, constipation or neuropathy were of
low incidence despite anti-MM activity. At least 71% of 24 relapsed
and refractory patients (median of three prior treatment regimens
including autologous stem cell transplant and thalidomide in 15
and 16 patients, respectively) evaluated in a dose-finding trial
experienced X25% paraprotein reduction. The median time to
best response was 2 months and the median treatment duration 6
months (Richardson et al, 2002). The most common grade 3 and 4
adverse events were neutropenia (grade 3 in 60%; grade 4 in 16%)
and thrombocytopenia (grade 3 in 20%). No thromboembolic
events were reported in this first monotherapy trial of lenalido-
mide in relapsed, refractory myeloma.
Other studies evaluated different dosing regimens in order to
minimise myelosuppression. A phase II study comparing 25mg
lenalidomide daily for 20 days vs 50mg daily for 10 days (both
regimens repeated every 28 days) in relapsed, refractory MM patients
reported that the 25mg dosing schedule produced a greater response
rate. A total of 40% of patients achieved X50% paraprotein
reduction with this dosing vs 15% using the higher dose/shorter
regimen. The estimated 12-month event-free survival was 30%, and
t h ee s t i m a t e do v e r a l ls u r v i v a lw a s6 1 %( Z a n g a r iet al, 2003).
A larger study evaluated 83 patients on one of two syncopated
dosing schedules, and found that 30mg daily (21 days out of every
28 days) caused less myelosuppression than 15mg b.i.d. (21 days
out of every 28), although response rates were similar. A total of
24% of patients achieved X50% paraprotein reduction, including
five patients with complete remission (6%). An additional 33% of
30 patients who progressed on lenalidomide alone achieved at least
a partial response (X50% paraprotein reduction) when dexa-
methasone was added (Richardson et al, 2003).
Lenalidomide has also been evaluated with Doxil, Vincristine and
dexamethasone (DVd) in relapsed, refractory MM (Baz et al, 2004)
and in combination with dexamethasone in newly diagnosed MM
(Rajkumar et al, 2004b). A phase I/II trial of lenalidomide in
refractory MM in combination with DVd (DVd-R) reported a 33%
(seven out of 21) complete and near complete response and a 66%
SWOG response. With prophylactic low-dose aspirin, one pulmon-
ary embolus occurred (in a refractory patient with renal failure,
performance status 3). Amoxicillin and acyclovir were also included
in the protocol. Grade 3 neutropenia occurred in two patients, but
there was no neutropenic sepsis. The other grade 3 adverse event
reported was neuropathy (one patient) (Hussein et al, 2004).
The first report of lenalidomide in newly diagnosed MM patients
was in combination with pulsed dexamethasone. The first analysis
of this phase II trial occurred when the trial had been running for
less than 6 months. Despite this short observation period, an 83%
(25 out of 30) objective response rate was observed. Patients
received 81mgday
 1 of aspirin as DVT prophylaxis. Although
various grade 3 nonhaematological toxicities were observed, there
were no toxicities Xgrade 4 and no deep vein thromboses
(Rajkumar et al, 2004b).
Two phase III randomised, double-blind, multicentre trials (US,
Canada, Australia and Europe) of lenalidomide plus high-dose
dexamethasone vs high-dose dexamethasone alone in previously
treated patients with MM were conducted in more than 700
relapsed/refractory patients. In March 2005, a protocol-specified
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determined that for both trials there was a statistically significant
improvement in time to disease progression in those patients
randomised to receive lenalidomide/dexamethasone vs dexametha-
sone alone. The prespecified P-value for stopping the trials
(Po0.0015) was exceeded and the safety profile was favourable.
Reported in a Scientific Symposium at the 2005 American Society
of Clinical Oncology (ASCO), the primary end point of time –to
disease progression in the lenalidomide plus dexamethasone arm
was 60.1 weeks (53.4 weeks – International) compared with a
median time –to disease progression of 20.7 weeks (20.6 –
International) for the dexamethasone alone arm (Pp0.00001).
Overall response rate with lenalidomide/dex was 61.2% (57.9% –
International) vs 22.8% (21.7% – International) with dex alone
(Pp0.001). The complete response rate was 26.5 and 13.6%
(lenalidomide/dex) vs 4.1 and 4.0% (dex alone) based on the
investigators’ assessment.
Increased side effects were noted in the combination arm,
compared with the dex/placebo arm, particularly grade 3/4
neutropenia and thrombocytopenia. Thromboembolic events were
noted in a greater percentage of US patients than International
patients (13.5 and 4.5%, respectively) (vs 3.5/3.4% in placebo/dex
arm), suggesting that further investigation is required to explain
this finding.
Treatment assignments will be unblinded, affording patients in
the control arm the opportunity to add lenalidomide to their
treatment regimen. These trials will form the basis for regulatory
filings.
Lenalidomide is also currently used in combination with other
therapies that have antimyeloma activity. A number of cooperative
groups in US and Europe are evaluating lenalidomide’s activity in
a variety of MM disease states (See Table 1).
MDS and other haematological malignancies
The myelodysplastic syndromes (MDS) are a spectrum of
malignant disorders of blood cell production, which affects over
250000 people worldwide, with the potential to develop into acute
leukaemia. Lenalidomide appears to be very active in restoring red
blood cell production in anaemic MDS patients, enabling them to
become independent of blood transfusions. Even more remarkable
is the effect of lenalidomide on patients with the 5q-syndrome (a
type of MDS) in which treatment can render undetectable the 5q-
chromosomal deletion that defines the condition. The apparent
efficacy of lenalidomide in this patient population led to the
submission of a New Drug Application (NDA) in April 2005
seeking approval to market this drug as a treatment for
transfusion-dependent MDS patients with a 5q deletion chromo-
somal abnormality.
In an open-label trial, 43 patients with primary MDS (French–
American–British (FAB) criteria), who were transfusion depen-
dent (74%) or had symptomatic anaemia (Hg o10gdl
 1), received
lenalidomide for 16 weeks (List et al, 2005a). Three oral dosing
schedules were evaluated: 25, 10 and 10mgday
 1 21 days of a
28-day cycle. Patients had derived no response to recombinant
erythropoietin, or had a low probability of responding (endogen-
ous serum level 4500mUml
 1). FAB classes were refractory
anaemia (RA-47%), RA with ringed sideroblasts (RARS-30%), RA
with excess blasts (RAEB-19%), RAEB in transformation (RAEB-t-
2%) and chronic myelomonocytic leukaemia (CMML-2%). Clonal
karyotypic abnormalities (X2 abnormal cells in metaphase) were
present in 46% of patients, including interstitial deletion of
chromosome 5q31.1 alone in 11 patients.
Response rate (modified International Working Group (IWG)
criteria) was 56%, with 20 out of 32 (63%) transfusion-dependent
patients achieving transfusion independence, and one out of 11
patients, who did not require transfusions, increasing haemoglobin
42gdl
 1. The median time to response varied with dose level (9
weeks at 25mgday
 1 to 11.5 weeks at 10mg syncopated dosing).
After a median of 81 weeks, the median duration of transfusion
independence had not been reached and the median haemoglobin
was 13.2gdl
 1.
An interesting finding was that the cytogenetic pattern was
significantly correlated with haematological response: 83% of
patients with 5q31.1 deletion responded vs 57% with a normal
karyotype and 15% with other cytogenetic abnormalities. FAB and
IPSS categories did not correlate with response. The median time
to response was more rapid in patients with 5q31.1 deletion than in
patients with a normal or other karyotype (8 weeks vs 11.2,
P¼0.029). Eleven out of 20 patients with clonal cytogenetic
abnormalities had cytogenetic responses, including 10 complete
cytogenetic remissions. Nine of the 10 complete cytogenetic
remissions occurred in patients with del(5)(q31.1). The median
time to cytogenetic remission was 8 weeks.
Neutropenia (65%, all Xgrade 3) and thrombocytopenia (74%
overall; 54% Xgrade 3) were the most common adverse events.
Severe myelosuppression was dose dependent and led to treatment
interruption or dose reduction in 58% of patients with the median
time to treatment resumption being 22 days. Other adverse events
were mild and infrequent. This initial indication of lenalidomide
activity in MDS led to phase II and III studies of lenalidomide in
MDS with and without 5q deletion.
Data reported in a plenary session at ASCO 2005 support the
previous findings. Of 148 transfusion-dependent MDS patients
with del5q31, participating in a multicentre phase II trial of
lenalidomide, 66% achieved transfusion independence (ITT
analysis), achieving a median haemoglobin increase of 5.3gdl
 1.
With a median duration of 58 weeks follow-up, 73% of responders
remained transfusion independent, and the median duration of
transfusion independence had not been reached. A greater
proportion of patients with an isolated, vs other del5q became
transfusion independent (69 vs 49%, P¼0.003). Cytogentic
response was noted in 70% of patients; 63% of these achieved
complete cytogenetic remission. The most common adverse events
were Xgrade 3 neutropenia or thrombocytopenia, which resolved
after dose reduction or after temporarily withholding lenalido-
mide. In total, 15 deaths occurred, two of which were suspected to
be drug related (List et al, 2005b). The data from this trial form the
basis for the NDA.
Lenalidomide is currently in phase II studies in myelofibrosis
with myeloid metaplasia. Clinically relevant responses have been
reported in four out of 15 (27%) patients. Improvement in anaemia
(two patients), splenomegaly (two patients) and/or constitutional
symptoms (three patients) occurred. One patient became transfu-
sion independent in addition to experiencing marked improve-
ment in constitutional symptoms. One patient’s haemoglobin
increased to 13.4gdl
 1 (from 8.3gdl
 1), leucocytes decreased
from 466 10
9 to within normal range and circulating blasts
disappeared (pretreatment level 9%) after lenalidomide therapy.
Grade 3 and 4 adverse events included neutropenia (five patients),
thrombocytopenia (three patients), rash and fatigue (two patients
each). Three patients experienced extreme thrombocytosis (Tefferi
et al, 2004) (steep increase in platelet count has also been reported
in a small number of patients taking thalidomide for myelofi-
brosis). One patient developed disseminated extramedullary
haematopoiesis after taking lenalidomide for 1 month.
Encouraging results have also been reported from a small trial of
lenalidomide in chronic lymphocytic leukaemia, with six out of
seven evaluable patients responding at day 30 (one CR, five PR,
one withdrew consent) (Miller et al, 2005). Lenalidomide is also
currently being evaluated in other haematological conditions
including amyloidosis and Waldenstrom’s macroglobulinaemia.
Lenalidomide has been granted both Orphan Drug and Fast
Track status by the FDA and Orphan Drug status for both MM and
MDS by the European Commission on MM and the European
Commission on MDS.
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Drug Indication Country Phase Status Comments and references
Multiple myeloma, monotherapy
Lenalidomide Multiple myeloma,
relapsed (n¼27)
USA I Completed First published report in MM (Richardson et al, 2002). A dose-escalating study with 24 evaluable
patients. Best responses in terms of reduction in serum M-protein in evaluated patients were
450% in seven out of 24 (30%), 425–50% in 10 out of 24 (42%), o25% in two out of 24 (8%)
patients. The maximum tolerated dose was 25mgday
 1. Grade 3 myelosuppression was apparent
with patients treated with 50mgday
 1. No somnolence or neuropathy was observed.
Lenalidomide7Dex Multiple myeloma,
relapsed/refractory
(n¼102)
Multicentre, USA II Completed Preliminary data from American Society of Hematology (ASH 2003) (Richardson et al, 2003)
comparing two dose levels (15mg b.i.d. vs 30mg qd  3 weeks with 1 week rest) of
lenalidomide7dexamethasone. Overall response rate was 38%, including 6%CR and 18%PR. In all,
33% of patients who received dex for progressive disease achieved XPR. Significant toxicities were
thrombocytopenia (18%) and neutropenia (28%). Lower frequency of myelosuppression with the
30mg qd cohort.
Lenalidomide Multiple myeloma,
relapsed/refractory
(n¼224)
Multicentre, USA II Ongoing Closed to enrolment. Preliminary data from International Myeloma Workshop (IMW) 2005
(Haematologica/The Hematology Journal; 90 (Suppl 1): 154, Abstract # PO.737) demonstrated
25% paraprotein reduction in 28% of patients with advanced MM and poor prognosis. Most
common grade 3 or 4 adverse events were neutropenia and thrombocytopenia.
Lenalidomide Multiple myeloma,
relapsed/refractory
(n¼100)
USA II Ongoing Closed to enrolment. Very early data on the first 38 patients (IMW 2003; Hematology Journal;
4(Suppl 1): S5–S7) reported that lenalidomide at 50mgqd  10 days repeated q 28 days
appeared inferior in terms of response (compared to 25mg qd  20) prompting dose modification
to 50mgqod
 1 10. No significant sedation or neurotoxicity was observed. Myelosuppression was
dose limiting.
Multiple myeloma, combination therapy
Lenalidomide+bortezomib Multiple myeloma,
relapsed/refractory
(n¼58)
USA I Ongoing Preliminary data from European Haematology Association (EHA) 2005 (Haematologica/The
Hematology Journal 2005; 90 (Suppl 1): 26–27, Abstract # PL5.04) on the first nine patients
treated: MTD was not reached in the first three cohorts. With a median of six cycles completed,
patients have tolerated bortezomib 1.0–1.3mgm
 2 and lenalidomide 5–10mgday
 1 without
DLT. All nine patients achieved minor response or stable disease. Grade 4 neutropenia (two
patients, o5 days duration) and grade 3 thrombocytpopenia was reported in four patients.
Lenalidomide+DVd (DVd-R)
Doxil, Vincristine, dexamethasone-
Revlimid
Multiple myeloma,
advanced relapsed/
refractory (n¼55)
USA I/II Ongoing Preliminary results from 2004 ASH meeting (Hussein et al, 2004) report that DVd-R is an extremely
effective regimen in refractory stage III MM. In 21 evaluable patients, the response rate (SWOG)
was 466%, including CR+near CR rate of 33%, with minimal toxicity. Maximum tolerated dose
defined as 10mgqd 21, q 28 days. The DLTs included sepsis/shock (at 15mg), non-neutropenic
sepsis (two patients), PE (one patient) and grade 3 neutropenia (two patients) and neuropathy
(one patient).
Lenalidomide plus dexamethasone Multiple myeloma,
newly diagnosed
(n¼34)
USA II Completed Preliminary results presented at 2004 American Society of Hematology (Rajkumar et al, 2004a,b)
suggest that lenalidomide /dexamethasone offers clinical benefit and is well tolerated in newly
diagnosed MM. Objective responses were reported in 25 out of 30 patients (83%). Daily aspirin
was given, no DVTs were reported. No gradeX4 toxicities were reported. A total of 33%
experienced various grade 3 toxicities.
Lenalidomide and dexamethasone
vs dexamethasone alone
Multiple myeloma,
refractory (n¼354)
Multicentre, USA/
Canada
III Ongoing Closed to enrolment. Results presented at the 2005 EHA (Haematologica/The Hematology Journal
2005; 90 (Suppl 2): 160, Abstract # 0402). Planned interim analysis by Independent Data
Monitoring Committee showed statistically significant increase in TTP in the lenalidomide/dex arm
(not reached at 60 weeks) vs 19.9 weeks in dex only arm. Overall response rate: 51.3% (len/dex ) vs
22.9% (dex); CR assessed by investigator: 19.5% (len/dex) vs 3.8% (dex).Well tolerated.
Lenalidomide and dexamethasone
vs dexamethasone alone
Multiple myeloma,
refractory (n¼351)
Multicentre,
International
III Ongoing Closed to enrolment. Planned interim analysis by Independent Data Monitoring Committee
showed statistically significant increase in the TTP in lenalidomide/dex arm (not reached at 47
weeks) vs 20.4 weeks in dex only arm (Dimopoulos et al, 2005). Overall response rate: 47.6% (len/
dex) vs 18.4% (dex); CR assessed by investigator: 9.1% (len/dex) vs 1.2% (dex). Well tolerated.
Lenalidomide and dexamethasone
vs dexamethasone alone
Multiple myeloma,
newly diagnosed (n¼
500)
USA, National Cancer
Institute (NCI) and
Southwest Oncology
group (SWOG), USA
III Ongoing No data reported as yet
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Drug Indication Country Phase Status Comments and references
Lenalidomide+dexamethasone vs
lenalidomide+low-dose
dexamethasone
Multiple myeloma
(n¼412)
USA, Eastern
Cooperative Oncology
Group (ECOG)
III Ongoing No data reported as yet
Lenalidomide+bortezomib vs
bortezomib
Multiple myeloma,
relapsing/progressing
on total therapy III
(n¼315)
USA III Ongoing No data reported as yet
Myelodysplastic syndromes
Lenalidomide Myelodysplastic
syndromes with 5q 
cytogenetic
abnormality (n¼151)
Multicentre, USA II Ongoing Closed to enrolment. Preliminary data on 148 patients with del 5q31, reported at ASCO 2005 (List
et al, 2005a,b) included transfusion independence in 64% of patients with a median Hb increase of
3.9gdl
 1 and 4-week time to response. Cytogentic response occurred in 76% of patients, with
complete cytogenetic remission in 55%. Pathologic complete response in 29%. After a median
follow up of 9.3 months, median response duration had not been reached and only 9% of patients
had failed therapy. Neutropenia and thrombocytopenia were the most common AEs necessitating
treatment interruption/dose reduction.
Lenalidomide MDS (n¼215) Multicentre, USA II Ongoing Closed to enrolment. Data from the 2005 International Symposium on MDS reported transfusion-
independence in 21% of 215 patients (ITT) with a median Hb increase of 3.0g/dl
 1. Of 169 low-
int-1 risk patients, 25% became transfusion-indepdendent and 43% achieved at least a minor
response. Neutropenia (19%) and thrombocytopenia (15%) were the most common adverse
effects.
Lenalidomide MDS (n¼45) USA II Ongoing Closed to enrolment. Data presented at the 2005 International Symposium on MDS (Raza et al,
abstract # P-121) from this study indicated substantial activity in low-risk MDS, including an overall
haematological response rate in 43 patients of 56%, with 20 out of 32 transfusion-dependent
patients achieving transfusion-independence. Response rate was highest in patients with deletion of
5q.31.1 (83%). Eleven out of 20 patients had cytogenetic remission, including complete cytogenetic
remission in 10. Neutropenia and thrombocytopenia were the most common adverse events.
Chronic lymphocytic leukaemia
Lenalidomide+rituximab Chronic lymphocytic
leukaemia, relapsed/
refractory (n¼29)
USA II Ongoing Preliminary data from EHA 2005 (Haematologica/The Hematology Journal 2005; 90(Suppl 2): 160,
Abstract # 97) on eight patients who completed 30 days of therapy: all eight patients responded
with decreases either in ALC or lymph node size. Two patients achieved CR/CRu, two PR and four
SD. Since no patients had PD, rituximab was not added. AEs included: grade 3/4 thrombocytopenia
(six patients); grade 3/4 neutropenia (three patients); flare reaction (three patients) and tumour lysis
syndrome (two patients). Antitumour activity was noted as early as 7 days after therapy.
Other – listed alphabetically by disease, phase
Lenalidomide Glioma, recurrent high-
grade (n¼36)
USA, National Cancer
Institute
I Completed Preliminary results on the first 18 patients, presented at the 2003 American Society of Clinical
Oncology meeting (Fine et al, abstract # 418), report that lenalidomide has been well tolerated
with only one drug-related toxicity 4grade 1 (grade 2 myelosuppression in patient with previous
BMT). One patient with rapidly progressive spinal hemangioblastomas, and two patients with
rapidly progressive glioblastoma experienced disease stabilisation for 6, 5 and 7 months,
respectively.
Lenalidomide Metastatic malignant
melanoma and other
advanced solid tumours
(n¼ 20)
UK I Completed First published report in solid tumours (Bartlett et al, 2004a,b). A total of 17 evaluable patients.
One partial response and two clear objective responses, such as resolution of subcutaneous and
cutaneous lesions. Evidence of T-cell activation and increased serum IL-12, GM-CSF and TNF-a was
found. No serious adverse effects were observed.
Lenalidomide Metastatic malignant
melanoma (n¼295)
Multicentre, (USA,
Canada)
III Completed Unblinded interim results determined that the trial would not demonstrate a statistically significant
treatment effect, although the safety profile was acceptable. On the recommendation of the Data
Monitoring Committee, the trial was halted.
Lenalidomide vs placebo Metastatic malignant
melanoma (n¼305)
Multicentre,
International
III Completed Unblinded interim results determined that the trial would not demonstrate a statistically significant
treatment effect, although the safety profile was acceptable. On the recommendation of the Data
Monitoring Committee, the trial was halted.
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KIMiDs in solid tumours
The first published study of lenalidomide in patients with solid
tumours suggests that lenalidomide has limited clinical activity in
patients with advanced and heavily pretreated metastatic malig-
nant melanoma and other solid cancers (Bartlett et al, 2004b). The
primary objective of this phase I study was to assess the safety and
tolerability of lenalidomide and in this regard there were no
serious adverse effects attributed to treatment. Also, analyses of
serum cytokines and peripheral blood cell-surface markers showed
conclusive evidence for immune activation. However, unblinded
interim results of two phase III lenalidomide monotherapy studies
in malignant melanoma patients determined that a statistically
significant treatment effect would not be achieved, although the
safety profile was acceptable. On the recommendation of the Data
Monitoring Committee, the programme was halted.
Lenalidomide is currently being evaluated in non-Hodgkin’s
lymphoma, NSCLC and cancers of the pancreas, prostate, brain,
kidneys and ovaries.
CONCLUSIONS
Thalidomide is now recognised as an agent with meaningful activity
in haematology and oncology. This activity provided the rationale for
the development of thalidomide analogues with the goal of
enhancing antineoplastic activity while reducing or eliminating
thalidomide-associated side effects. The IMiDs
s have antiangio-
genic, direct antitumour, anti-inflammatory and immune stimula-
tory properties. A particular challenge is to characterise how these
properties interact within the physiological milieu of disease states.
As this review has documented, lenalidomide has entered the
clinic for the treatment of various cancers. Pharmacological,
preclinical and clinical data clearly demonstrate qualitative and
quantitative differences between thalidomide and lenalidomide.
The reported remarkable safety and efficacy of lenalidomide in the
treatment of MDS and MM support regulatory filings in these
indications. In addition, other neoplastic conditions will be
assessed for sensitivity to lenalidomide. As with most agents in
haematology/oncology, the authors believe that appropriate
combination therapy involving lenalidomide will lead to highly
effective therapy for treating a variety of malignant conditions. We
look forward to understanding how various combination therapies
can improve the management of afflicted patients.
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